JiangXi Tianxin Pharmaceutical Co Ltd
SSE:603235
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
JiangXi Tianxin Pharmaceutical Co Ltd
Accounts Receivables
JiangXi Tianxin Pharmaceutical Co Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
JiangXi Tianxin Pharmaceutical Co Ltd
SSE:603235
|
Accounts Receivables
¥288.8m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Accounts Receivables
¥6B
|
CAGR 3-Years
70%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Accounts Receivables
¥3.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Accounts Receivables
¥5.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
9%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Accounts Receivables
¥10.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
23%
|
CAGR 10-Years
25%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Accounts Receivables
¥106.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
JiangXi Tianxin Pharmaceutical Co Ltd
Glance View
Perched in the vibrant province of Jiangxi, China, JiangXi Tianxin Pharmaceutical Co., Ltd. has carved a niche for itself as a formidable player in the pharmaceutical industry. Established with a clear vision to fuse traditional Chinese medicine with state-of-the-art technological advancements, the company specializes in the development and production of high-quality pharmaceutical products. JiangXi Tianxin's journey is a testament to its commitment to providing effective health solutions, emphasizing the importance of research and development to foster innovation within its product lines. The company operates with a holistic perspective, aiming to address various health concerns by integrating traditional wisdom with modern pharmaceutical practices. At the heart of its operations, JiangXi Tianxin's business model thrives on a diversified product portfolio, which spans active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. This strategic diversification allows the company to mitigate risks associated with market fluctuations while tapping into multiple revenue streams. By focusing on the production of APIs, JiangXi Tianxin ensures a robust supply chain necessary for developing essential medicines. Furthermore, its ability to manufacture a broad spectrum of products facilitates profitability through an economy of scale, allowing the company to maintain competitive pricing. By aligning its operational strategies with market demand and regulatory standards, JiangXi Tianxin not only sustains its growth but also fortifies its standing as a trusted pharmaceutical entity in both domestic and international markets.
See Also
What is JiangXi Tianxin Pharmaceutical Co Ltd's Accounts Receivables?
Accounts Receivables
288.8m
CNY
Based on the financial report for Dec 31, 2024, JiangXi Tianxin Pharmaceutical Co Ltd's Accounts Receivables amounts to 288.8m CNY.
What is JiangXi Tianxin Pharmaceutical Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
5%
Over the last year, the Accounts Receivables growth was 27%. The average annual Accounts Receivables growth rates for JiangXi Tianxin Pharmaceutical Co Ltd have been -5% over the past three years , 5% over the past five years .